Neurology | Phase I Developments | Pipeline Prospector

Pfizer Inc

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Contact Supplier

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

Lead Product(s): PF-05251749

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Biogen

Deal Size: $710.0 million Upfront Cash: $75.0 million

Deal Type: Acquisition January 13, 2020

Details:

With this purchase, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep Wake Rhythm Disorder in Parkinson’s disease.

Alterity Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Alterity Therapeutics Meeting with US FDA Provides Development Pathway for ATH434

Lead Product(s): ATH434

Therapeutic Area: Neurology Product Name: ATH434

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 30, 2020

Details:

The pre-IND (Investigational New Drug) meeting was to obtain input on the clinical development plan for ATH434, including feedback on the Phase 2 study design.

Alector

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002

Lead Product(s): AL002

Therapeutic Area: Neurology Product Name: AL002

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 25, 2020

Details:

Antibody-mediated engagement of TREM2 expanded unique subpopulations of metabolically active and proliferating microglia in a human TREM2 expressing mouse model of Alzheimer’s disease.

BrainStorm Cell Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for AZ

Lead Product(s): MSC-NTF cells

Therapeutic Area: Neurology Product Name: NurOwn

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 24, 2020

Details:

As part of the newly announced program, the Company is planning a multi-national Phase 2 clinical trial to evaluate the safety and efficacy of NurOwn treatment in patients with prodromal to mild Alzheimer's disease.

Atara Biotherapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Atara Biotherapeutics Enrolled First Patient in Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of M.S

Lead Product(s): ATA188

Therapeutic Area: Neurology Product Name: ATA188

Highest Development Status: Phase I Product Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 17, 2020

Details:

Based on the Phase 1a study findings showing sustained disability improvements in active MS patients, the Phase 1b study will assess clinical outcomes including disability measures, physical and cognitive performance, biomarkers and MRI imaging, as well as safety.

Athira Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Athira Pharma Closes $85 Million Series B Financing

Lead Product(s): NDX-1017

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Perceptive Advisors

Deal Size: $85.0 million Upfront Cash: Undisclosed

Deal Type: Series B Financing June 04, 2020

Details:

The funding supports the company to advance its lead therapeutic candidate, NDX-1017, into Phase 2/3 clinical development and explore the potential of their pipeline of compounds across a range of central and peripheral neurodegenerative and neuropsychiatric indications.

AlzeCure Pharma AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

AlzeCure Announces Positive Data From Clinical Study with ACD856

Lead Product(s): ACD856

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 04, 2020

Details:

Data show that ACD856, has a good pharmacokinetic profile with a significantly shorter human half-life than its predecessor ACD855 and that the candidate is suitable for further clinical development such as oral treatment of Alzheimer's disease, among others.

Athira Pharma

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Athira Pharma to Present at Jefferies Virtual Global Healthcare Conference

Lead Product(s): NDX-1017

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 28, 2020

Details:

Athira will present on the current state of the company and the advancement of lead therapeutic candidate, NDX-1017, for Alzheimer’s disease as well as pipeline development for other disease indications.

Alterity Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Lead Product(s): ATH434

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

The abstract, presentation and article share findings from Alterity's completed Phase 1 trial of leading drug candidate ATH434, which evaluated the safety, tolerability, and pharmacokinetics in healthy adult and older adult volunteers.

Anavex Life Sciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

IFT Annual Expo

Participation Not Confirmed

Update your events

Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)

Lead Product(s): Anavex 3-71

Therapeutic Area: Neurology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 21, 2020

Details:

Anavex got approval from Australian Human Research Ethics Committee has to initiate the First-in-Human FIH clinical study of ANAVEX®3-71 (AF710B), a small molecule targeting sigma-1 and M1 muscarinic receptors that is designed to be beneficial for neurodegenerative diseases.

Find

Find Neurology Drugs in Phase I Clinical Development

Phase I

Product Type

Companies

Pfizer Inc

Biogen to buy early-stage potential Alzheimer's, Parkinson's treatment from Pfizer

Alterity Therapeutics

Alterity Therapeutics Meeting with US FDA Provides Development Pathway for ATH434

Alector

Alector Announces Publication of Preclinical and Phase 1 Data Validating Potential of AL002

BrainStorm Cell Therapeutics

BrainStorm Expands Clinical Pipeline to Evaluate NurOwn® for AZ

Atara Biotherapeutics

Atara Biotherapeutics Enrolled First Patient in Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 in Progressive Forms of M.S

Athira Pharma

Athira Pharma Closes $85 Million Series B Financing

AlzeCure Pharma AB

AlzeCure Announces Positive Data From Clinical Study with ACD856

Athira Pharma

Athira Pharma to Present at Jefferies Virtual Global Healthcare Conference

Alterity Therapeutics

Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology

Anavex Life Sciences

Anavex Life Sciences Announces Initiation of First-in-Human Phase 1 Study of ANAVEX®3-71 (AF710B)